Elton Satusky

Elton Satusky

Partner

Extensive Corporate Experience

Elton specializes in public and private corporate finance and corporate law and governance, and also has considerable M&A and venture capital experience.
Life Sciences Insider

Elton serves as co-editor of The Life Sciences Report, a semi-annual newsletter on the life sciences industry published by the firm.

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Elton represents both public and private enterprises as their outside general counsel and serves as a key strategic advisor from their inception throughout their life cycle. He advises on complex venture capital and corporate finance transactions, corporate law and governance, mergers and acquisitions, and public offerings.

Elton has a particular focus on companies in the medical device, biotechnology, pharmaceutical, diagnostic, and digital health sectors and serves as co-editor of The Life Sciences Report, a semi-annual newsletter on the life sciences industry published by the firm. He is also a board member and founder of US-Japan Medtech Frontiers, a nonprofit corporation that has hosted annual cross-border healthcare conferences in Japan for the past decade. In addition, Elton is a frequent guest lecturer at universities, industry and trade group conferences, accelerators, and incubators.

Experience

Education

LL.B., Osgoode Hall Law School, York University, Toronto, 1996
Two years towards Bachelor of Business Administration, York University, Toronto, 1993

Admissions

Law Society of Ontario
State Bar of California

Credentials

Education

LL.B., Osgoode Hall Law School, York University, Toronto, 1996
Two years towards Bachelor of Business Administration, York University, Toronto, 1993

Admissions

Law Society of Ontario
State Bar of California

Recent Insights

Client Highlights

On September 3, 2024, Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital. The proceeds from the financing will be used to fund the clinical development of CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, and to support the development of the company’s portfolio of discovery programs built with its MXMO macrocycle platform.

Learn More

Client Highlights

On July 15, 2024, Digestiva, a leading food biotech company, successfully closed its Series A equity financing round, raising $18.4 million. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments, and existing investors The March Fund and Astanor. Digestiva's groundbreaking enzyme technology platform was initially discovered by co-founder Dr. Wilson Mak, in the lab of UC Davis faculty member Dr. Justin Siegel, a global leader in enzyme discovery, development, and design. Wilson Sonsini Goodrich & Rosati represented Digestiva in the transaction.

Learn More

View All

Recent Events

Affiliated Programs

Wilson Sonsini is pleased to sponsor the US-Japan Healthcare Innovation Conference, which will take place during Japan Healthcare Week. The conference will feature events in Tokyo (Nov. 11, 12) and Kumamoto (Nov. 14). This year, the theme is "Building a Transpacific Ecosystem in Healthcare.”

Learn More

WSGR Events

Wilson Sonsini Goodrich & Rosati’s 31st Annual Medical Device & Digital Health Conference will address topics of critical importance to medical device and digital health companies today, including key healthcare regulatory considerations, the relationship between intellectual property and valuation, a look back at 2023’s fundraising and deals, and how 2024 is shaping up along with partnering strategies in the current market.

Learn More